Antimanic and long-lasting mood stabilizing effect of memantine in bipolar I mood disorder: Two case reports

Journal of Clinical Psychopharmacology

Volumn 33, Issue 5, 2013, Pages 715-717

  Serra, Giulia ^a   De Chiara, Lavinia ^a   Koukopoulos, Athanasios ^a   Serra, Gino ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; CHLORPROMAZINE; DISULFIRAM; HALOPERIDOL; LITHIUM; MEMANTINE; QUETIAPINE; TRIAZOLAM; VALPROIC ACID; VENLAFAXINE;

ABSENCE OF SIDE EFFECTS; ADULT; AKATHISIA; ALCOHOL ABUSE; ALCOHOLISM; ALZHEIMER DISEASE; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BIPOLAR MANIA; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DISEASE SEVERITY; DRUG ABUSE; DRUG DEPENDENCE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EUPHORIA; FAMILY HISTORY; FEMALE; HEREDITY; HUMAN; INSOMNIA; LETTER; MAJOR DEPRESSION; MANIA; MEDICAL HISTORY; MONOTHERAPY; MOOD DISORDER; OUTPATIENT CARE; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; PSYCHOLOGICAL WELL BEING; PUERPERAL DEPRESSION; SLEEP TIME; SOCIAL INTERACTION; SUICIDE ATTEMPT; TREATMENT DURATION; TREATMENT REFUSAL; TREATMENT RESPONSE;

ADULT; AFFECT; ANTIMANIC AGENTS; BIPOLAR DISORDER; FEMALE; HUMANS; MEMANTINE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 84883783192     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31829b62ba     Document Type: Letter

References (20)

1. Koukopoulos A, Reginaldi D, Serra G, et al. Antimanic and mood stabilizing effect of memantine as augmenting agent in treatment resistant bipolar disorder. Bipolar Disord. 2010;12:348-349
2. Koukopoulos A, Serra G, Koukopolos AE, et al. The sustained mood-stabilizing effect of memantine in the management of treatment-resistant bipolar disorders: Findings from a 12-month naturalistic trial. J Affect Disord. 2012;136:163-166
3. Serra G. A 3-year, open-label naturalistic study of adjunctive memantine in treatment-resistant bipolar disorder. Int Clin Psychopharmacol. 2012;28:e22. (abstract presented at the International Review of Bipolar Disorders meeting in Nice, 2012
4. Sani G, Serra G, Kotzalidis GD, et al. The role of memantine in the treatment of psychiatric disorders other than the dementias a review of current preclinical and clinical evidence. CNS Drugs. 2012;26(8):663-690
5. Keck PE, Hsu HA, Papadakis K, et al. Memantine efficacy and safety in patients with acute mania associated with bipolar I disorder: A pilot evaluation. Clin Neuropharmacol. 2009;32(4):199-204
6. Zarate CA, Singh JB, Quiroz JA, et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry. 2006; 163:153-155
7. Koukopoulos A, Ghaemi SN. The primacy of mania: A reconsideration of mood disorders. Eur Psychiatry. 2009;24(2):125-134
8. Baldessarini RJ, Tondo L. Recurrence risk in bipolar manic-depressive disorders after discontinuing lithium maintenance treatment: An overview. Clin Drug Investig. 1998; 15(4):337-351
9. Tondo L, Vázquez G, Baldessarini RJ. Mania associated with antidepressant treatment: Comprehensive meta-Analytic review. Acta Psychiatr Scand. 2010;121(6):404-414
10. McNamara JO. Pharmacotherapy of the epilepsies. In: Brunton L, Chabner B, Knollman B, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 12th ed. New York, NY: Mc Graw Hill Medical; 2011;21:583-607
11. Jones RW. A review comparing the safety and tolerability of memantine with the acetylcholinesterase inhibitors. Int J Geriatr Psychiatry. 2010;24:547-553
12. Demontis F, Cubeddu A, Serra G. Memantine prevents the bipolar-like behaviour induced by chronic imipramine in rats. Int Clin Psychopharmacol. 2012;28:e35Ye36. (paper presented at the International Review of Bipolar Disorders meeting in Nice, 2012
13. Serra G, Argiolas A, Klimek V, et al. Chronic treatment with antidepressants prevents the inhibitory effect of small doses of apomorphine on dopamine synthesis and motor activity. Life Sci. 1979;25:415-424
14. Serra G, Collu M, D'Aquila PS, et al. Role of mesolimbic dopamine system in the mechanism of action of antidepressants. Pharmacol Toxicol. 1992;71(1):72-85
15. D'Aquila PS, Peana AT, Panin F, et al. Reversal of antidepressant-induced dopaminergic behavioral supersensitivity after long-Term chronic imipramine withdrawal. Eur J Pharmacol. 2004;458:129-134
16. D'Aquila PS, Panin F, Serra G. Long-Term imipramine withdrawal induces a depressive-like behaviour in the forced swimming test. Eur J Pharmacol. 2004; 492:61-63
17. Serra G. Memantine for treating bipolar mood disorders resistant to conventional treatments. EP 2 218 450 A1 (Published 18-08-2010, Bulletin 2010/33
18. La Spada AR. Memantine strikes the perfect balance. Nat Med. 2009;15(12):1355-1356
19. Ongür D, Jensen JE, Prescot AP, et al. Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania. Biol Psychiatry. 2008;64(8):718-726
20. Atmara H, Yildirin H. Neurochemical ingredient of hippocampus in patients with bipolar depression. Depress Res Treat. 2012;1-6